MAPS, Columbia U Partner on First MDMA Couples Therapy Study
Enrollment targets are modest but specific: 50–100 anonymous survey responses and 10–20 confidential interviews, backed by Columbia University IRB...
Halneuron® Phase 2b Trial Reaches 50% Enrollment Milestone
Interim data from Dogwood Therapeutics’ ongoing Phase 2b HALT-CINP study point to a favorable operational and clinical signal: a...
Pulmovant Completes Enrollment for Phase 2 PH-ILD Study
In early clinical testing, a single inhaled dose of mosliciguat reduced pulmonary vascular resistance by up to 38% and...
Onward Study Offers Hope for SCI Blood Pressure Control
Feasibility data published in 2025 reported immediate, sustained increases in blood pressure with implant-based spinal cord stimulation in people...
New Trial Data: Comparable Survival Despite Genetic Mismatch
One-year overall survival exceeded 80% across all mismatch levels in the prospective, 268-patient ACCESS trial of mismatched unrelated donor...
Dewpoint Launches Promising Cancer Trial for Solid Tumors
Dewpoint Therapeutics has dosed the first patient in a Phase 1a/2a study of DPTX3186, a first-in-class small molecule that...
Adial Applauds New Path for Substance Use Disorder Trials
Congress’s 2026 appropriations package for HHS embeds a clear directive: FDA and NIDA are to collaborate on alternative clinical...
Pivotal DEVOTE Study Results on High-Dose Nusinersen in SMA
Treatment-naïve infants with SMA receiving Biogen’s higher-dose nusinersen regimen achieved a 26.19-point advantage on CHOP-INTEND versus a prespecified matched...
How Early-Stage Intelligence Determines Late-Stage Success
Why competitive insight in the earliest stages of developing a therapy can determine ultimate success By Alex Angelopoulos, Life...
Breaking the Transcription Barrier: How eSource Redefines Clinical Research Workflows
The traditional clinical trial landscape is undergoing a digital metamorphosis. For decades, the reliance on manual transcription—moving data from...